Verrica Ready To Target Pediatric Dermatologists With First Molluscum Therapy
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.
You may also be interested in...
Asia Deal Watch: Takeda Keeps Up Hectic Deals Pace Via Three New Alliances
Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.
Verrica’s Molluscum Product Set Back By FDA Usage Questions
Verrica got a complete response rather than approval for its drug/device combo for molluscum, but says the FDA only needs additional information on product changes for safe usage by clinicians.
Finance Watch: Biotech Stocks Down, But Holding Up Better Than Broader Indices
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.